Regeneron: adjusted EPS up 13% in Q2

(CercleFinance.com) - Regeneron reports Q2 sales of $3,547m, up 12% y-o-y.


The US biotech company reported adjusted net income (non-GAAP) of $1,351m, up 14%, and adjusted EPS of $11.56, up 13%.

Our Q2 financial results reflect the continued momentum of our business, illustrated by double-digit growth in sales and earnings, management said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.